Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8743871 | 0.88 | CYP1A2 (0.46) | NFE2L2CYP1A2EPHX1SMN1; SMN2SIGMAR1 | |
| SCHEMBL11224710 | 0.88 | CYP1A2 (0.46) | NFE2L2CYP1A2EPHX1SMN1; SMN2SIGMAR1 | |
| SCHEMBL21938959 | 0.85 | CYP1A2 (0.44) | NFE2L2CYP1A2EPHX1SMN1; SMN2SIGMAR1 | |
| SCHEMBL8986251 | 0.85 | NFE2L2 (0.42) | NFE2L2CYP1A2EPHX1SMN1; SMN2SIGMAR1 | |
| SCHEMBL24042735 | 0.80 | NFE2L2 (0.39) | NFE2L2CYP1A2EPHX1SMN1; SMN2SIGMAR1 | |
| SCHEMBL28329353 | 0.80 | NFE2L2 (0.38) | NFE2L2CYP1A2EPHX1SMN1; SMN2SIGMAR1 | |
| SCHEMBL7536085 | 0.79 | NAAA (0.40) | — | |
| SCHEMBL9864420 | 0.77 | NFE2L2 (0.39) | NFE2L2CYP1A2EPHX1SMN1; SMN2SIGMAR1 | |
| SCHEMBL6937266 | 0.77 | CYP1A2 (0.54) | NFE2L2CYP1A2EPHX1SMN1; SMN2SIGMAR1 | |
| SCHEMBL20938745 | 0.77 | SIGMAR1 (0.50) | NFE2L2CYP1A2SMN1; SMN2SIGMAR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934215-A1 | ISOTOPICALLY SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | Nycomed GmbH (DE) | 2008-06-25 | — | — | EP | disclosed |
| EP-1926714-A1 | ISOTOPICALLY SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | Nycomed GmbH (DE) | 2008-06-04 | — | — | EP | disclosed |
| US-20080119510-A1 | Substituted Imidazo [4,5-B] Pyridines As Inhibitors Of Gastric Acid Secretion | ALTANA PHARMA AG (DE) | 2008-05-22 | — | — | US | disclosed |
| EP-1910313-A1 | 6-THIOAMIDE SUBSTITUTED BENZIMIDAZOLES | Nycomed GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008015196-A1 | 5-,7-BIS-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES | NYCOMED GMBH (DE) | 2008-02-07 | — | — | WO | disclosed |
| US-7326718-B2 | 8-Substituted imidazopyridines | ALTANA PHARMA AG (DE) | 2008-02-05 | — | — | US | disclosed |
| EP-1824850-A2 | SUBSTITUTED IMIDAZO[4,5-b]PYRIDINES AS INHIBITORS OF GASTRIC ACID SECRETION | Nycomed GmbH (DE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007039464-A1 | ISOTOPICALLY SUBSTITUTED IMIDAZOPYRIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007023135-A1 | ISOTOPICALLY SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | NYCOMED GMBH (DE) | 2007-03-01 | — | — | WO | disclosed |
| EP-1756067-A1 | 7-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC ACID SECRETION | Altana Pharma AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005111000-A1 | 7-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC ACID SECRETION | ALTANA PHARMA AG (DE) | 2005-11-24 | — | — | WO | disclosed |
| EP-1565465-A1 | 8-SUBSTITUTED IMIDAZOPYRIDINES | ALTANA Pharma AG (DE) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005026164-A1 | PHARMACOLOGICALLY ACTIVE IMIDAZO[4,5-C]PYRIDINES | ALTANA PHARMA AG (DE) | 2005-03-24 | — | — | WO | disclosed |
| US-20040235882-A1 | Amino-substituted imidazopyridines for the treatment of gastrointestial diseases | ALTANA PHARMA AG (DE) | 2004-11-25 | — | — | US | disclosed |
| US-20040235883-A1 | Alkyl-substituted imidazopyridines for the treatment of gastrointestinal disorders | ALTANA PHARMA AG (DE) | 2004-11-25 | — | — | US | disclosed |
| WO-2004046144-A1 | 8-SUBSTITUTED IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2004-06-03 | — | — | WO | disclosed |
| EP-1419156-A1 | ALKYL-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA Pharma AG (DE) | 2004-05-19 | — | — | EP | disclosed |
| EP-1417208-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | ALTANA Pharma AG (DE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003016310-A1 | ALKYL-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA PHARMA AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003014120-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | ALTANA PHARMA AG (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235883-A1 | Alkyl-substituted imidazopyridines for the treatment of gastrointestinal disorders | SLC10A2, ALPI, SI | NFE2L2 1443/4885CYP1A2 26/4885EPHX1 1714/4885 |
| US-20080119510-A1 | Substituted Imidazo [4,5-B] Pyridines As Inhibitors Of Gastric Acid Secretion | GIPR, CCKBR, GRPR | NFE2L2 2963/4885CYP1A2 247/4885EPHX1 1363/4885 |
| US-20040235882-A1 | Amino-substituted imidazopyridines for the treatment of gastrointestial diseases | SLC10A2, ALPI, FABP6 | NFE2L2 943/4885CYP1A2 144/4885EPHX1 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.